12:00 AM
 | 
Feb 28, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Aflibercept: Completed Phase II enrollment

Regeneron disclosed in its 4Q10 earnings that partner sanofi-aventis completed enrollment of about 230 patients in the open-label Phase II AFFIRM trial comparing aflibercept in combination with leucovorin, 5-fluorouracil (5-FU) and oxaliplatin...

Read the full 136 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >